UAE HEART FAILURE TREATMENT DRUGS MARKET ANALYSIS

Market News

UAE Heart Failure Treatment Drugs Market: Key Developments

On January 20, 2021, Merck & Co., Inc., a U.S.-based multinational pharmaceutical company, announced the launch of Verquvo, a soluble guanylate cyclase to reduce risk of cardiovascular death and heart failure hospitalization following hospitalization for heart failure or need for outpatient intravenous diuretics in adults with symptomatic heart failure and ejection fraction less than 45%. The approval is based on the results of pivotal phase 3 victoria trials. Trials were conducted on 5,050 adult patients with worsening heart failure event. A worsening heart failure event was defined as heart failure hospitalization within six months or less prior to randomization or use of outpatient IV diuretics for heart failure within three months or less prior to randomization. In VICTORIA, the primary endpoint was a composite of time to first event of cardiovascular death or hospitalization for heart failure. The median follow-up for the primary endpoint was 11 months. VERQUVO was superior to placebo in reducing the risk of cardiovascular death or heart failure hospitalization based on a time-to-event analysis.

On February 4, 2022, Cytokinetics Incorporated U.S. based biopharmaceutical company announced the acceptance of New Drug Application (NDA) for Omecamtiv Mecarbil, an investigational, selective, and small molecule cardiac myosin activator for the treatment of heart failure with reduced ejection fraction. The NDA is supported by results from global approach to lowering adverse cardiac outcomes through improving contractility in heart failure (GALACTIC-HF) phase 3 cardiovascular outcomes clinical trials of omecamtiv mecarbil that enrolled 8,000 patients in 35 countries across 945 sites. GALACTIC-HF demonstrated a statistically significant effect of treatment with omecamtiv mecarbil to reduce the risk of the primary composite endpoint of Cardiovascular (CV) death or heart failure events (heart failure hospitalization and other urgent treatment for heart failure) compared to placebo in patients treated with standard of care. Additional analyses from GALACTIC-HF demonstrated a greater treatment effect of omecamtiv mecarbil in patients with lower Left Ventricular Ejection Fraction (LVEF), as well as other characteristics that may indicate worsening heart failure.

On June 14, 2023, the UAE joined forces with health authorities in Syria to carry out crucial heart operations in underprivileged communities. The Cardiac Care initiative will be carried out by Emirates Red Crescent, UAE affiliate of the International Federation of Red Cross and Red Crescent Societies in conjunction with the Health Directorate in the Latakia governorate, in North-Western Syria, Al Bassel Cardiology Hospital in Latakia and a specialist medical team. The project will offer catheterization and heart operations, and help address concerns over the prevalence of heart disease in the area.

On April 26, 2022, RAK Hospital, part of Arabian Healthcare Group, a UAE-based private hospital, introduced a new cardiac defibrillator therapy that can save patients on the verge of a heart failure. A CRT-D is a special device for patients who are at a high risk of a sudden cardiac arrest. While functioning like a normal pacemaker to treat slow heart rhythms, a CRT-D device also delivers small electrical impulses to the left and right ventricles to help them contract at the same time. This helps the heart pump more efficiently.